Katharina Fink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katharina Fink has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Fredrik Piehl
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
8 shared publications - Kyla A. McKay
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
8 shared publications - Björn Evertsson
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
4 shared publications - Fredrik Sandesjö
Neuropediatric Unit, Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden; Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
4 shared publications - Jan Hillert
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
4 shared publications - Anders Svenningsson
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
3 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (6) , e200642
Late-Onset Neutropenia After Rituximab in Multiple Sclerosis
Background and ObjectivesLate-onset neutropenia (LON) is a rare, transient reduction in absolute neutrophil count (ANC) associated with anti-CD20 therapies. In multiple sclerosis (MS), data regardi...
- 1 November 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (6) , e200642
Open AccessLate-Onset Neutropenia After Rituximab in Multiple Sclerosis
Background and ObjectivesLate-onset neutropenia (LON) is a rare, transient reduction in absolute neutrophil count (ANC) associated with anti-CD20 therapies. In multiple sclerosis (MS), data regardi...
- Open Access
Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis
Background: Evidence on menopausal hormone replacement therapy (HRT) and disability progression in women with multiple sclerosis (MS) is limited, particularly in the era of high-efficacy disease-modifying therapy. We estimated the association between systemic HRT and sustained disability progression and recurring relapses in a contemporary national cohort. Methods: In a nationwide Swedish registry-based cohort, we followed women with MS aged 40 to 60 years entering from 2006 through 2024, with follow-up through 2025, under a new-user design. Systemic HRT was modeled as time-varying current use and quarterly oral-equivalent dose categories. Outcomes were sustained Expanded Disability Status Scale (EDSS) 4.0, sustained EDSS 6.0, and recurring relapses. Cox models adjusted for baseline covariates and time-varying age and disease-modifying therapy (DMT) class. Results: Among 7,623 women, 1,192 (15.6%) initiated HRT. Current HRT use was associated with a lower hazard of sustained EDSS 4.0 (adjusted hazard ratio [aHR] 0.70, 95% confidence interval [CI] 0.51 to 0.96) but not sustained EDSS 6.0 (aHR 0.80, 95% CI 0.55 to 1.16) or recurring relapses (aHR 1.00, 95% CI 0.74 to 1.36). Dose categories showed no consistent gradient. Raising the cohort-entry age floor to 50 years gave a consistent EDSS 4.0 estimate (aHR 0.62, 95% CI 0.40 to 0.95). Conclusions: HRT was not associated with increased relapse risk or severe disability progression. The lower hazard of sustained EDSS 4.0 was not mirrored at EDSS 6.0 and showed no dose gradient. Given menopausal status was unmeasured, replication in cohorts with verified menopausal status is required for clear clinical interpretation.
Open AccessHormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis
Background: Evidence on menopausal hormone replacement therapy (HRT) and disability progression in women with multiple sclerosis (MS) is limited, particularly in the era of high-efficacy disease-modifying therapy. We estimated the association between systemic HRT and sustained disability progression and recurring relapses in a contemporary national cohort. Methods: In a nationwide Swedish registry-based cohort, we followed women with MS aged 40 to 60 years entering from 2006 through 2024, with follow-up through 2025, under a new-user design. Systemic HRT was modeled as time-varying current use and quarterly oral-equivalent dose categories. Outcomes were sustained Expanded Disability Status Scale (EDSS) 4.0, sustained EDSS 6.0, and recurring relapses. Cox models adjusted for baseline covariates and time-varying age and disease-modifying therapy (DMT) class. Results: Among 7,623 women, 1,192 (15.6%) initiated HRT. Current HRT use was associated with a lower hazard of sustained EDSS 4.0 (adjusted hazard ratio [aHR] 0.70, 95% confidence interval [CI] 0.51 to 0.96) but not sustained EDSS 6.0 (aHR 0.80, 95% CI 0.55 to 1.16) or recurring relapses (aHR 1.00, 95% CI 0.74 to 1.36). Dose categories showed no consistent gradient. Raising the cohort-entry age floor to 50 years gave a consistent EDSS 4.0 estimate (aHR 0.62, 95% CI 0.40 to 0.95). Conclusions: HRT was not associated with increased relapse risk or severe disability progression. The lower hazard of sustained EDSS 4.0 was not mirrored at EDSS 6.0 and showed no dose gradient. Given menopausal status was unmeasured, replication in cohorts with verified menopausal status is required for clear clinical interpretation.
- Open Access
More tests, higher scores: Testing frequency and SDMT differences between natalizumab and rituximab
Background: The Symbol Digit Modalities Test (SDMT) measures information processing speed, and repeated testing can increase scores through practice effects. However, how differences in testing frequency bear on comparisons between disease-modifying therapies (DMTs) in real-world cohorts has not been fully explored. Objective: To compare SDMT trajectories between natalizumab and rituximab users and quantify the association of the testing process with those trajectories. Methods: Using the Swedish MS Registry, we studied adults with relapsing-remitting MS initiating natalizumab or rituximab (2010–2024) with ≥2 on-treatment SDMT assessments. Mixed-effects models with restricted cubic spline time were sequentially adjusted; log cumulative test number was the practice-effect adjustment. Results: Among 2,458 individuals, natalizumab initiators were tested twice as often as rituximab initiators (1.6 vs. 0.8 tests/year). The predicted natalizumab-minus-rituximab SDMT difference at 3 years was 7.0 points (95% CI 5.7–8.3) unadjusted and 1.6 (0.7–2.6) after full adjustment including cumulative test number; at 1 year it fell from 4.4 (3.3–5.4) to −0.3 (−1.2 to 0.6). Conclusion: Adjustment for cumulative test number substantially attenuated the SDMT difference between natalizumab and rituximab, leaving a small residual difference of uncertain clinical importance and underscoring the need to account for testing frequency in real-world comparisons.
Open AccessMore tests, higher scores: Testing frequency and SDMT differences between natalizumab and rituximab
Background: The Symbol Digit Modalities Test (SDMT) measures information processing speed, and repeated testing can increase scores through practice effects. However, how differences in testing frequency bear on comparisons between disease-modifying therapies (DMTs) in real-world cohorts has not been fully explored. Objective: To compare SDMT trajectories between natalizumab and rituximab users and quantify the association of the testing process with those trajectories. Methods: Using the Swedish MS Registry, we studied adults with relapsing-remitting MS initiating natalizumab or rituximab (2010–2024) with ≥2 on-treatment SDMT assessments. Mixed-effects models with restricted cubic spline time were sequentially adjusted; log cumulative test number was the practice-effect adjustment. Results: Among 2,458 individuals, natalizumab initiators were tested twice as often as rituximab initiators (1.6 vs. 0.8 tests/year). The predicted natalizumab-minus-rituximab SDMT difference at 3 years was 7.0 points (95% CI 5.7–8.3) unadjusted and 1.6 (0.7–2.6) after full adjustment including cumulative test number; at 1 year it fell from 4.4 (3.3–5.4) to −0.3 (−1.2 to 0.6). Conclusion: Adjustment for cumulative test number substantially attenuated the SDMT difference between natalizumab and rituximab, leaving a small residual difference of uncertain clinical importance and underscoring the need to account for testing frequency in real-world comparisons.
- Open Access
Live Birth Rates Among Women With Multiple Sclerosis in Sweden, 2004 to 2022: A Population-Based Registry Study
Background: Women with multiple sclerosis (MS) have fewer children than other women, but whether this narrowed as pregnancy evidence became reassuring and treatment options expanded is uncertain. Objective: To compare live birth trends from 2004 to 2022 between women with MS and all Swedish women. Methods: Linking the Swedish MS, National Patient, and Medical Birth Registers with national statistics, we compared age-standardised live birth rates, counted expected births at national rates, and estimated adjusted annual live-birth risk ratios in a matched comparison sample. Results: Women with MS (n=10,452; 76,989 woman-years) had 3,577 children, about 1,200 (25%) fewer than expected (observed-to-expected ratio 0.75, 95% CI 0.72 to 0.77). Standardised rate ratios were below 1 annually (median 0.77). Observed-to-expected ratios were 0.73 (0.68 to 0.79) in 2004 to 2008 and 0.70 (0.65 to 0.75) in 2019 to 2022 (population-by-period interaction p=0.31). Age- and region-adjusted risk ratios ranged from 0.75 to 0.86 across periods (heterogeneity p=0.020), closest to 1 in 2009 to 2013. Conclusion: Women with MS had about one quarter fewer live births than other Swedish women, and the difference was similar in the first and last periods.
Open AccessLive Birth Rates Among Women With Multiple Sclerosis in Sweden, 2004 to 2022: A Population-Based Registry Study
Background: Women with multiple sclerosis (MS) have fewer children than other women, but whether this narrowed as pregnancy evidence became reassuring and treatment options expanded is uncertain. Objective: To compare live birth trends from 2004 to 2022 between women with MS and all Swedish women. Methods: Linking the Swedish MS, National Patient, and Medical Birth Registers with national statistics, we compared age-standardised live birth rates, counted expected births at national rates, and estimated adjusted annual live-birth risk ratios in a matched comparison sample. Results: Women with MS (n=10,452; 76,989 woman-years) had 3,577 children, about 1,200 (25%) fewer than expected (observed-to-expected ratio 0.75, 95% CI 0.72 to 0.77). Standardised rate ratios were below 1 annually (median 0.77). Observed-to-expected ratios were 0.73 (0.68 to 0.79) in 2004 to 2008 and 0.70 (0.65 to 0.75) in 2019 to 2022 (population-by-period interaction p=0.31). Age- and region-adjusted risk ratios ranged from 0.75 to 0.86 across periods (heterogeneity p=0.020), closest to 1 in 2009 to 2013. Conclusion: Women with MS had about one quarter fewer live births than other Swedish women, and the difference was similar in the first and last periods.
- Open Access
- 31 May 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (8) , 829-838
Treatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study
Background: Comparative studies in paediatric-onset multiple sclerosis (PoMS) that also include highly effective monoclonal antibody therapies are rare. Objective: To compare treatment persistence, as a proxy of effectiveness and tolerability, across disease-modifying therapies (DMTs). Methods: Nationwide cohort study using Swedish MS Registry data on individuals with MS onset before age 18 from 2000 to 2024. Treatment persistence was analysed using Kaplan–Meier and Cox models, adjusted for demographics and treatment epoch. Results: We included 383 individuals (69.2% female; median onset age 15.8 and 17.2 years at first DMT start), observed for a median 10.1 years (interquartile range (IQR): 5.5–15.5), yielding 934 treatment episodes: rituximab (272), injectables (263), natalizumab (248), fingolimod (86) and dimethyl fumarate (65). Median age at any treatment initiation, regardless of treatment sequence, was 18.9 years, with a median Expanded Disability Status Scale (EDSS) score of 1.5 (IQR: 0.0–2.0). Treatment persistence never dropped below 50% for rituximab, while median persistence was 35.6 months for natalizumab (95% confidence interval (CI): 28.8–44.9), 34.7 for dimethyl fumarate (95% CI: 21.7–56.9), 32.0 for fingolimod (95% CI: 21.1–48.1) and 17.6 for injectables (95% CI: 14.4–20.8). Compared to injectables, adjusted hazard ratios (HRs) for discontinuation were significantly lower for rituximab (0.09; 95% CI: 0.07–0.12), natalizumab (0.39; 95% CI: 0.31–0.48), fingolimod (0.41; 95% CI: 0.30–0.55) and dimethyl fumarate (0.49; 95% CI: 0.36–0.68). Conclusion: Rituximab displayed the highest treatment persistence, supporting B-cell depletion as a first-line option in PoMS.
- 31 May 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (8) , 829-838
Open AccessTreatment persistence in paediatric-onset multiple sclerosis: A Swedish nationwide registry study
Background: Comparative studies in paediatric-onset multiple sclerosis (PoMS) that also include highly effective monoclonal antibody therapies are rare. Objective: To compare treatment persistence, as a proxy of effectiveness and tolerability, across disease-modifying therapies (DMTs). Methods: Nationwide cohort study using Swedish MS Registry data on individuals with MS onset before age 18 from 2000 to 2024. Treatment persistence was analysed using Kaplan–Meier and Cox models, adjusted for demographics and treatment epoch. Results: We included 383 individuals (69.2% female; median onset age 15.8 and 17.2 years at first DMT start), observed for a median 10.1 years (interquartile range (IQR): 5.5–15.5), yielding 934 treatment episodes: rituximab (272), injectables (263), natalizumab (248), fingolimod (86) and dimethyl fumarate (65). Median age at any treatment initiation, regardless of treatment sequence, was 18.9 years, with a median Expanded Disability Status Scale (EDSS) score of 1.5 (IQR: 0.0–2.0). Treatment persistence never dropped below 50% for rituximab, while median persistence was 35.6 months for natalizumab (95% confidence interval (CI): 28.8–44.9), 34.7 for dimethyl fumarate (95% CI: 21.7–56.9), 32.0 for fingolimod (95% CI: 21.1–48.1) and 17.6 for injectables (95% CI: 14.4–20.8). Compared to injectables, adjusted hazard ratios (HRs) for discontinuation were significantly lower for rituximab (0.09; 95% CI: 0.07–0.12), natalizumab (0.39; 95% CI: 0.31–0.48), fingolimod (0.41; 95% CI: 0.30–0.55) and dimethyl fumarate (0.49; 95% CI: 0.36–0.68). Conclusion: Rituximab displayed the highest treatment persistence, supporting B-cell depletion as a first-line option in PoMS.
- Open Access
- 20 January 2026
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2026 (1)
Changes in Multiple Sclerosis Clinical Care and Outcomes During the COVID‐19 Era: A Population‐Wide Study
Introduction: The Coronavirus Disease 2019 (COVID‐19) pandemic has had a profound impact on healthcare systems globally, necessitating significant adaptations in the management of chronic conditions such as multiple sclerosis (MS). In Sweden, where a unique approach to pandemic mitigation was adopted, the effects on MS clinical care remain a subject of interest. This population‐based study is aimed at assessing changes in MS clinical care during the COVID‐19 era compared to the prepandemic period. Methods: Using the data from the Swedish MS Registry, encompassing the periods from January 29, 2018, to February 29, 2020 (pre‐COVID‐19 era), and from March 1, 2020, to April 1, 2022 (COVID‐19 era), we analyzed MS incidence rates, clinic visits, relapse rates, initiation of disease‐modifying treatments (DMTs), and dosing intervals for infusion medications. Statistical analyses, including interrupted time series and mixed Poisson regression models, were employed to assess changes in outcomes while adjusting for relevant covariates. Results: Our analysis included 19,959 MS patients. While there was a decrease in MS diagnoses during the pandemic period, this difference was not statistically significant. In contrast, a significant reduction in frequencies of physical clinical visits and relapse rates compared to the prepandemic period was evident. Treatment strategies shifted, with decreased utilization of anti‐CD20 therapies and increased use of platform and other high‐efficacy non–anti‐CD20 DMTs. Dosing intervals for infusion medications were also extended during the COVID‐19 era. Conclusion: The findings underscore the substantial impact of the pandemic on MS clinical care practices and data capture in Sweden. Understanding these changes is crucial for monitoring or quality control of MS care, informing future research endeavors which access the Swedish MS Registry to measure disease outcomes in this population. The study highlights the responsiveness of healthcare systems in adapting to important challenges while emphasizing the importance of ongoing monitoring and adaptation in MS management practices.
- 20 January 2026
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2026 (1)
Open AccessChanges in Multiple Sclerosis Clinical Care and Outcomes During the COVID‐19 Era: A Population‐Wide Study
Introduction: The Coronavirus Disease 2019 (COVID‐19) pandemic has had a profound impact on healthcare systems globally, necessitating significant adaptations in the management of chronic conditions such as multiple sclerosis (MS). In Sweden, where a unique approach to pandemic mitigation was adopted, the effects on MS clinical care remain a subject of interest. This population‐based study is aimed at assessing changes in MS clinical care during the COVID‐19 era compared to the prepandemic period. Methods: Using the data from the Swedish MS Registry, encompassing the periods from January 29, 2018, to February 29, 2020 (pre‐COVID‐19 era), and from March 1, 2020, to April 1, 2022 (COVID‐19 era), we analyzed MS incidence rates, clinic visits, relapse rates, initiation of disease‐modifying treatments (DMTs), and dosing intervals for infusion medications. Statistical analyses, including interrupted time series and mixed Poisson regression models, were employed to assess changes in outcomes while adjusting for relevant covariates. Results: Our analysis included 19,959 MS patients. While there was a decrease in MS diagnoses during the pandemic period, this difference was not statistically significant. In contrast, a significant reduction in frequencies of physical clinical visits and relapse rates compared to the prepandemic period was evident. Treatment strategies shifted, with decreased utilization of anti‐CD20 therapies and increased use of platform and other high‐efficacy non–anti‐CD20 DMTs. Dosing intervals for infusion medications were also extended during the COVID‐19 era. Conclusion: The findings underscore the substantial impact of the pandemic on MS clinical care practices and data capture in Sweden. Understanding these changes is crucial for monitoring or quality control of MS care, informing future research endeavors which access the Swedish MS Registry to measure disease outcomes in this population. The study highlights the responsiveness of healthcare systems in adapting to important challenges while emphasizing the importance of ongoing monitoring and adaptation in MS management practices.
- Open Access
- 24 September 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (4) , 1319-1331
Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis
Granulocytes play a well-established role in the pathogenesis of brain tissue damage in neuromyelitis optica spectrum disorder (NMOSD). The release of granulocyte activation markers (GAM) into CSF has recently been shown to distinguish NMOSD from multiple sclerosis (MS) with high accuracy. However, their pathogenetic role in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is less clear, and their usefulness for diagnostic differentiation is unknown. This observational cohort study by eight tertiary centres in Europe and Japan included 244 CSF samples from patients with MOGAD (n = 71), NMOSD (n = 48), MS (n = 125) and control persons (n = 19). CSF levels of GAM [neutrophil elastase, myeloperoxidase, neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-8 and 9 (MMP-8, MMP-9)], astrocyte damage markers [ADM: glial fibrillary acidic protein (GFAP), S100B], and complement factors C5 and C5a were analysed by capillary ELISA (Ella™) or Luminex®. The primary outcome was the capacity of these markers to differentiate MOGAD, NMOSD and MS in the acute (≤21 days post-exacerbation) stage, and the correlation of GAM with C5 and C5a. Secondary analyses included the correlations of these markers with disability severity, measured by the Expanded Disability Status Scale (EDSS). GAM (except for MMP-9), ADM and C5/C5a levels peaked at onset of disease exacerbation of MOGAD and NMOSD (regardless of aquaporin-4 antibody status), and were significantly higher than in MS. MMP-9 levels were continuously increased in MS over MOGAD and NMOSD, both in acute and subacute/chronic stages. C5 and C5a were equally increased over MS in acute stages of MOGAD and NMOSD. A logistic model and receiver operating characteristics analyses incorporating GAM and C5 displayed high discriminatory power between MOGAD/NMOSD versus MS [area under the curve (AUC) = 0.880], NMOSD versus MS (AUC = 0.837) and MOGAD versus MS (AUC = 0.925) in acute stages. Accordingly, increased ADM levels in NMOSD differentiated NMOSD from MS and MOGAD (AUC = 0.897 and 0.843, respectively). GAM levels correlated with EDSS scores in MOGAD and NMOSD, but not in MS, while those of ADM correlated with disability in NMOSD, but not in MOGAD and MS. Determining CSF levels of GAM and C5/C5a, and of ADM provide a biology-driven approach to differentiate MOGAD, NMOSD and MS. Their measurement can be processed faster and with similar accuracy than with most autoantibody assays, enabling timely initiation of appropriate therapy in acute presentations. The correlation between GAM and C5/C5a levels with neurological impairment in MOGAD and NMOSD corroborates their role as effectors of neural damage, supporting the acute stage use of inhibitors of C5 activation.
- 24 September 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (4) , 1319-1331
Open AccessGranulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis
Granulocytes play a well-established role in the pathogenesis of brain tissue damage in neuromyelitis optica spectrum disorder (NMOSD). The release of granulocyte activation markers (GAM) into CSF has recently been shown to distinguish NMOSD from multiple sclerosis (MS) with high accuracy. However, their pathogenetic role in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is less clear, and their usefulness for diagnostic differentiation is unknown. This observational cohort study by eight tertiary centres in Europe and Japan included 244 CSF samples from patients with MOGAD (n = 71), NMOSD (n = 48), MS (n = 125) and control persons (n = 19). CSF levels of GAM [neutrophil elastase, myeloperoxidase, neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-8 and 9 (MMP-8, MMP-9)], astrocyte damage markers [ADM: glial fibrillary acidic protein (GFAP), S100B], and complement factors C5 and C5a were analysed by capillary ELISA (Ella™) or Luminex®. The primary outcome was the capacity of these markers to differentiate MOGAD, NMOSD and MS in the acute (≤21 days post-exacerbation) stage, and the correlation of GAM with C5 and C5a. Secondary analyses included the correlations of these markers with disability severity, measured by the Expanded Disability Status Scale (EDSS). GAM (except for MMP-9), ADM and C5/C5a levels peaked at onset of disease exacerbation of MOGAD and NMOSD (regardless of aquaporin-4 antibody status), and were significantly higher than in MS. MMP-9 levels were continuously increased in MS over MOGAD and NMOSD, both in acute and subacute/chronic stages. C5 and C5a were equally increased over MS in acute stages of MOGAD and NMOSD. A logistic model and receiver operating characteristics analyses incorporating GAM and C5 displayed high discriminatory power between MOGAD/NMOSD versus MS [area under the curve (AUC) = 0.880], NMOSD versus MS (AUC = 0.837) and MOGAD versus MS (AUC = 0.925) in acute stages. Accordingly, increased ADM levels in NMOSD differentiated NMOSD from MS and MOGAD (AUC = 0.897 and 0.843, respectively). GAM levels correlated with EDSS scores in MOGAD and NMOSD, but not in MS, while those of ADM correlated with disability in NMOSD, but not in MOGAD and MS. Determining CSF levels of GAM and C5/C5a, and of ADM provide a biology-driven approach to differentiate MOGAD, NMOSD and MS. Their measurement can be processed faster and with similar accuracy than with most autoantibody assays, enabling timely initiation of appropriate therapy in acute presentations. The correlation between GAM and C5/C5a levels with neurological impairment in MOGAD and NMOSD corroborates their role as effectors of neural damage, supporting the acute stage use of inhibitors of C5 activation.
- Open Access
- 24 July 2025
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 40 (8) , 905-913
Completeness and generalizability of the Swedish MS register
The Swedish Multiple Sclerosis (MS) Register is a nationwide clinical tool and research database. Its generalizability to the broader MS population has not been previously assessed. We aimed to quantify the register’s completeness and potential disparities between those who were included and those who were not. Using linked national registers, we identified persons with MS through December 2020 as those with ≥ 3 MS diagnoses in the National Patient Register. We assessed the MS register’s completeness and compared characteristics between included and non-included persons, using overlap weighting to account for age differences. Among 21,320 prevalent (2020) and 7,355 incident (2011–2020) MS cases, the completeness of the MS register was 85% and 87%, respectively, but varied by county (67–94% in 2020). Prevalent cases not included in the register were older (mean 62.4 vs. 52.3 years) and more likely to have no salaried income (55.3% vs. 30.5%); had fewer years of education (20.8% vs. 12.0% with ≤ 9 years); more often been hospitalized (41.5% vs. 32.2%); and collected more unique prescribed drugs (median 7 vs. 5 drugs per year). Incident cases were also older at first MS diagnosis (mean 50.3 vs. 39.2 years). All differences were attenuated by adjusting for age, although disparities remained. The Swedish MS Register demonstrates high completeness, but may not fully represent older persons with MS, those diagnosed later in life, and those of lower socioeconomic status. These limitations should be considered when interpreting findings based on the register’s data.
- 24 July 2025
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 40 (8) , 905-913
Open AccessCompleteness and generalizability of the Swedish MS register
The Swedish Multiple Sclerosis (MS) Register is a nationwide clinical tool and research database. Its generalizability to the broader MS population has not been previously assessed. We aimed to quantify the register’s completeness and potential disparities between those who were included and those who were not. Using linked national registers, we identified persons with MS through December 2020 as those with ≥ 3 MS diagnoses in the National Patient Register. We assessed the MS register’s completeness and compared characteristics between included and non-included persons, using overlap weighting to account for age differences. Among 21,320 prevalent (2020) and 7,355 incident (2011–2020) MS cases, the completeness of the MS register was 85% and 87%, respectively, but varied by county (67–94% in 2020). Prevalent cases not included in the register were older (mean 62.4 vs. 52.3 years) and more likely to have no salaried income (55.3% vs. 30.5%); had fewer years of education (20.8% vs. 12.0% with ≤ 9 years); more often been hospitalized (41.5% vs. 32.2%); and collected more unique prescribed drugs (median 7 vs. 5 drugs per year). Incident cases were also older at first MS diagnosis (mean 50.3 vs. 39.2 years). All differences were attenuated by adjusting for age, although disparities remained. The Swedish MS Register demonstrates high completeness, but may not fully represent older persons with MS, those diagnosed later in life, and those of lower socioeconomic status. These limitations should be considered when interpreting findings based on the register’s data.
- Open Access
- 1 January 2025
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 11 (1)
Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis
Few controlled trials of disease-modifying therapies (DMTs) have been conducted on the pediatric-onset multiple sclerosis (PoMS) population, leading to extensive off-label use of therapies approved only for adults. This highlights the need for real-world evidence to guide clinical practice. Clinical registries can offer high-quality data, but limitations such as missing and erroneous information must be considered. This validation study compared Swedish Multiple Sclerosis registry data from 122 PoMS patients to medical records. Generally (≥89%), data were confirmed. However, missing data exceeded 30% for rituximab infusions, magnetic resonance imaging, and relapses. Overall, the registry provides valid, real-world data on DMT use in PoMS.
- 1 January 2025
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 11 (1)
Open AccessValidation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis
Few controlled trials of disease-modifying therapies (DMTs) have been conducted on the pediatric-onset multiple sclerosis (PoMS) population, leading to extensive off-label use of therapies approved only for adults. This highlights the need for real-world evidence to guide clinical practice. Clinical registries can offer high-quality data, but limitations such as missing and erroneous information must be considered. This validation study compared Swedish Multiple Sclerosis registry data from 122 PoMS patients to medical records. Generally (≥89%), data were confirmed. However, missing data exceeded 30% for rituximab infusions, magnetic resonance imaging, and relapses. Overall, the registry provides valid, real-world data on DMT use in PoMS.
- Open Access
- 25 May 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (8) , e16331
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
Background and purpose: Mechanisms behind hypogammaglobulinaemia during rituximab treatment are poorly understood.Methods: In this register‐based multi‐centre retrospective cohort study of multiple sclerosis (MS) patients in Sweden, 2745 patients from six participating Swedish MS centres were identified via the Swedish MS registry and included between 14 March 2008 and 25 January 2021. The exposure was treatment with at least one dose of rituximab for MS or clinically isolated syndrome, including data on treatment duration and doses. The degree of yearly decrease in immunoglobulin G (IgG) and immunoglobulin M (IgM) levels was evaluated.Results: The mean decrease in IgG was 0.27 (95% confidence interval 0.17–0.36) g/L per year on rituximab treatment, slightly less in older patients, and without significant difference between sexes. IgG or IgM below the lower limit of normal (<6.7 or <0.27 g/L) was observed in 8.8% and 8.3% of patients, respectively, as nadir measurements. Six out of 2745 patients (0.2%) developed severe hypogammaglobulinaemia (IgG below 4.0 g/L) during the study period. Time on rituximab and accumulated dose were the main predictors for IgG decrease. Previous treatment with fingolimod and natalizumab, but not teriflunomide, dimethyl fumarate, interferons or glatiramer acetate, were significantly associated with lower baseline IgG levels by 0.80–1.03 g/L, compared with treatment‐naïve patients. Switching from dimethyl fumarate or interferons was associated with an additional IgG decline of 0.14–0.19 g/L per year, compared to untreated.Conclusions: Accumulated dose and time on rituximab treatment are associated with a modest but significant decline in immunoglobulin levels. Previous MS therapies may influence additional IgG decline.
- 25 May 2024
- Published by Wiley in European Journal of Neurology
- Vol. 31 (8) , e16331
Open AccessHypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
Background and purpose: Mechanisms behind hypogammaglobulinaemia during rituximab treatment are poorly understood.Methods: In this register‐based multi‐centre retrospective cohort study of multiple sclerosis (MS) patients in Sweden, 2745 patients from six participating Swedish MS centres were identified via the Swedish MS registry and included between 14 March 2008 and 25 January 2021. The exposure was treatment with at least one dose of rituximab for MS or clinically isolated syndrome, including data on treatment duration and doses. The degree of yearly decrease in immunoglobulin G (IgG) and immunoglobulin M (IgM) levels was evaluated.Results: The mean decrease in IgG was 0.27 (95% confidence interval 0.17–0.36) g/L per year on rituximab treatment, slightly less in older patients, and without significant difference between sexes. IgG or IgM below the lower limit of normal (<6.7 or <0.27 g/L) was observed in 8.8% and 8.3% of patients, respectively, as nadir measurements. Six out of 2745 patients (0.2%) developed severe hypogammaglobulinaemia (IgG below 4.0 g/L) during the study period. Time on rituximab and accumulated dose were the main predictors for IgG decrease. Previous treatment with fingolimod and natalizumab, but not teriflunomide, dimethyl fumarate, interferons or glatiramer acetate, were significantly associated with lower baseline IgG levels by 0.80–1.03 g/L, compared with treatment‐naïve patients. Switching from dimethyl fumarate or interferons was associated with an additional IgG decline of 0.14–0.19 g/L per year, compared to untreated.Conclusions: Accumulated dose and time on rituximab treatment are associated with a modest but significant decline in immunoglobulin levels. Previous MS therapies may influence additional IgG decline.